GlobeNewswire·Oct 12, 2026, 4:05 PM ET

Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026

Apnimed announced that five abstracts regarding its investigational drug AD109 & obstructive sleep apnea (OSA) data will be presented at the CHEST 2026 Annual Meeting in Phoenix from October 18–21.
Three abstracts feature Phase 3 program data for AD109 (aroxybutynin 2.3 mg/atomoxetine 75 mg), including two late-breaking presentations: a rapid-fire oral session on post-menopausal women & a poster on baseline hypoxic burden as a blood pressure response marker.
Two additional abstracts present real-world US data on the OSA burden, covering impacts on quality of life & work productivity, as well as patient-physician agreement on symptoms at diagnosis.
A panel discussion titled "New Medications for Treatment of OSA: The SynAIRgy and LunAIRo Trials" will address trial results, potential applications to OSA management, and considerations beyond the Apnea-Hypopnea Index (AHI).
Apnimed will host a sponsored learning theater session on October 21 featuring speakers Amir Sharafkhaneh & Dennis Hwang to discuss clinical evidence for AD109 & the importance of multidimensional assessment for OSA.
AD109 is a once-daily oral combination of aroxybutynin & atomoxetine designed to target the neuromuscular root cause of upper airway collapse & improve oxygenation during sleep.
Apnimed's New Drug Application (NDA) for AD109 is under FDA review with a PDUFA goal date of February 28, 2027, following two completed Phase 3 trials for mild, moderate, & severe OSA.